Clinical implications of vasohibin-1 in esophageal carcinoma cells: Inhibition of cell growth and migration

Ma,Deliang; Li,Jingye; Wang,Jinbao; Sun,Zhigang; Wang,Kai

doi:10.3892/mmr.2017.6726

Clinical implications of vasohibin-1 in esophageal carcinoma cells: Inhibition of cell growth and migration

Authors:
- Deliang Ma
- Jingye Li
- Jinbao Wang
- Zhigang Sun
- Kai Wang
View Affiliations

Affiliations: Department of Oncology, Yishui Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China, Department of General Surgery, Yishui Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China, Central Laboratory, Yishui Central Hospital of Linyi, Linyi, Shandong 276400, P.R. China, Department of Breast Surgery, Weifang People's Hospital, Weifang, Shandong 261041, P.R. China
Published online on: June 8, 2017 https://doi.org/10.3892/mmr.2017.6726
Pages: 1479-1485

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

As one of the first-established negative feedback regulators of angiogenesis, mesenchymal vasohibin-1 (VASH1) serves important roles in the progression and prognosis of various types of tumor. However, the clinical implications of VASH1 in esophageal carcinoma (EC) cells have not been reported and the direct effects of VASH1 on EC cells remain unknown. In the present study, the expression of VASH1 in EC cells was observed using immunohistochemistry and western blotting; a χ2 test was used to analyze the correlation of VASH1 with clinical parameters, and it was observed that VASH1 was negatively-correlated with tumor size (r=‑0.399; P<0.01) and invasion depth (r=‑0.318; P<0.01). Survival analysis demonstrated that VASH1 was positively‑correlated with increased overall survival (P=0.039) and disease free survival (P=0.012). The direct effects of VASH1 on EC cells were analyzed by altering VASH1 expression, and it was observed that downregulation of VASH1 increased proliferation, clone formation and the migratory ability of EC9706 cells, whereas upregulation of VASH1 inhibited proliferation, clone formation and the migratory ability of EC1 cells. The results of the present study demonstrated that VASH1 in EC cells was negatively‑correlated with progression and poor prognosis of patients with EC. VASH1 was able to directly inhibit the growth and migration of EC cells.

View Figures

View References

1	Zhang H, Chen W, Duan CJ and Zhang CF: Overexpression of HSPA2 is correlated with poor prognosis in esophageal squamous cell carcinoma. World J Surg Oncol. 11:1412013. View Article : Google Scholar : PubMed/NCBI
2	Zhu YH, Yang F, Zhang SS, Zeng TT, Xie X and Guan XY: High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. Int J Clin Exp Pathol. 6:2497–2505. 2013.PubMed/NCBI
3	Li M, Yang X, Zhang J, Shi H, Hang Q, Huang X, Liu G, Zhu J, He S and Wang H: Effects of EHD2 interference on migration of esophageal squamous cell carcinoma. Med Oncol. 30:3962013. View Article : Google Scholar : PubMed/NCBI
4	Hasan MR, Sharma R, Saraya A, Chattopadhyay TK, DattaGupta S, Walfish PG, Chauhan SS and Ralhan R: Slug is a predictor of poor prognosis in esophageal squamous cell carcinoma patients. PLoS One. 8:e828462013. View Article : Google Scholar : PubMed/NCBI
5	Kim SG: What is the next step after endoscopic resection of superficial esophageal squamous cell carcinoma? Gut Liver. 9:693–694. 2015. View Article : Google Scholar : PubMed/NCBI
6	Kern J, Steurer M, Gastl G, Gunsilius E and Untergasser G: Vasohibin inhibits angiogenic sprouting in vitro and supports vascular maturation processes in vivo. BMC Cancer. 9:2842009. View Article : Google Scholar : PubMed/NCBI
7	Watanabe K, Hasegawa Y, Yamashita H, Shimizu K, Ding Y, Abe M, Ohta H, Imagawa K, Hojo K, Maki H, et al: Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J Clin Invest. 114:898–907. 2004. View Article : Google Scholar : PubMed/NCBI
8	Sato Y: The vasohibin family. Pharmaceuticals. 3:433–440. 2010. View Article : Google Scholar : PubMed/NCBI
9	Tamaki K, Moriya T, Sato Y, Ishida T, Maruo Y, Yoshinaga K, Ohuchi N and Sasano H: Vasohibin-1 in human breast carcinoma: A potential negative feedback regulator of angiogenesis. Cancer Sci. 100:88–94. 2009. View Article : Google Scholar : PubMed/NCBI
10	Zhao G, Yang Y, Tang Y, Han R and Sun Y: Reduced expression of vasohibin-1 is associated with clinicopathological features in renal cell carcinoma. Med Oncol. 29:3325–3334. 2012. View Article : Google Scholar : PubMed/NCBI
11	Wang Q, Tian X, Zhang C and Wang Q: Upregulation of vasohibin-1 expression with angiogenesis and poor prognosis of hepatocellular carcinoma after curative surgery. Med Oncol. 29:2727–2736. 2012. View Article : Google Scholar : PubMed/NCBI
12	Kosaka T, Miyazaki Y, Miyajima A, Mikami S, Hayashi Y, Tanaka N, Nagata H, Kikuchi E, Nakagawa K, Okada Y, et al: The prognostic significance of vasohibin-1 expression in patients with prostate cancer. Br J Cancer. 108:2123–2129. 2013. View Article : Google Scholar : PubMed/NCBI
13	Kimura H, Miyashita H, Suzuki Y, Kobayashi M, Watanabe K, Sonoda H, Ohta H, Fujiwara T, Shimosegawa T and Sato Y: Distinctive localization and opposed roles of vasohibin-1 and vasohibin-2 in the regulation of angiogenesis. Blood. 113:4810–4818. 2009. View Article : Google Scholar : PubMed/NCBI
14	Shen Z, Seppänen H, Kauttu T, Vainionpää S, Ye Y, Wang S, Mustonen H and Puolakkainen P: Vasohibin-1 expression is regulated by transforming growth factor-β/bone morphogenic protein signaling pathway between tumor-associated macrophages and pancreatic cancer cells. J Interferon Cytokine Res. 33:428–433. 2013. View Article : Google Scholar : PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
16	Jiang YX, Du ZM, Jiao L, Shao Q, Fu S, Shao JY, Zhu XF, Ernberg I and Li YH: Inhibition of MiR-155 suppresses cell migration in nasopharyngeal carcinoma through targeting ZDHHC2. Int J Clin Exp Med. 8:8472–8484. 2015.PubMed/NCBI
17	Zhang Y and Lin Q: MicroRNA-145 inhibits migration and invasion by down-regulating FSCN1 in lung cancer. Int J Clin Exp Med. 8:8794–8802. 2015.PubMed/NCBI
18	Zhang T, Yu TT, Zhang DM, Hou XM, Liu XJ, Zhao D and Shan L: Vasohibin-1 expression detected by immunohistochemistry correlates with prognosis in non-small cell lung cancer. Med Oncol. 31:9632014. View Article : Google Scholar : PubMed/NCBI
19	Yan Y, Shen Z, Ye Y, Jiang K, Zhang H, Shen C, Mustonen H, Puolakkainen P and Wang S: A novel molecular marker of prognosis in colorectal cancer: Vasohibin-1. Med Oncol. 31:8162014. View Article : Google Scholar : PubMed/NCBI
20	Miyashita H, Watanabe T, Hayashi H, Suzuki Y, Nakamura T, Ito S, Ono M, Hoshikawa Y, Okada Y, Kondo T and Sato Y: Angiogenesis inhibitor vasohibin-1 enhances stress resistance of endothelial cells via induction of SOD2 and SIRT1. PLoS One. 7:e464592012. View Article : Google Scholar : PubMed/NCBI
21	Miyashita H, Suzuki H, Ohkuchi A and Sato Y: Mutual balance between vasohibin-1 and soluble VEGFR-1 in endothelial cells. Pharmaceuticals (Basel). 4:782–793. 2011. View Article : Google Scholar :
22	Lv ZD, Zhang L, Liu XP, Jin LY, Dong Q, Li FN, Wang HB and Kong B: NKD1 down-regulation is associated with poor prognosis in breast invasive ductal carcinoma. Int J Clin Exp Pathol. 8:4015–4021. 2015.PubMed/NCBI
23	Shen Y, Zhang F, Lan H, Chen K, Zhang Q, Xie G, Teng L and Jin K: FRZB up-regulation is correlated with hepatic metastasis and poor prognosis in colon carcinoma patients with hepatic metastasis. Int J Clin Exp Pathol. 8:4083–4090. 2015.PubMed/NCBI
24	Strong AL, Ohlstein JF, Biagas BA, Rhodes LV, Pei DT, Tucker HA, Llamas C, Bowles AC, Dutreil MF, Zhang S, et al: Leptin produced by obese adipose stromal/stem cells enhances proliferation and metastasis of estrogen receptor positive breast cancers. Breast Cancer Res. 17:1122015. View Article : Google Scholar : PubMed/NCBI
25	Pathak R, Philizaire M and Mujtaba S: Dichotomy in the Epigenetic Mark Lysine Acetylation is Critical for the Proliferation of Prostate Cancer Cells. Cancers (Basel). 7:1622–1642. 2015. View Article : Google Scholar : PubMed/NCBI
26	Liu S, Han B, Zhang Q, Dou J, Wang F, Lin W, Sun Y and Peng G: Vasohibin-1 suppresses colon cancer. Oncotarget. 6:7880–7898. 2015. View Article : Google Scholar : PubMed/NCBI
27	Rusckowski M, Wang Y, Blankenberg FG, Levashova Z, Backer MV and Backer JM: Targeted scVEGF/(177)Lu radiopharmaceutical inhibits growth of metastases and can be effectively combined with chemotherapy. EJNMMI Res. 6:42016. View Article : Google Scholar : PubMed/NCBI
28	Vanajothi R and Srinivasan P: An anthraquinone derivative from Luffa acutangula induces apoptosis in human lung cancer cell line NCI-H460 through p53-dependent pathway. J Recept Signal Transduct Res. 36:292–302. 2016. View Article : Google Scholar : PubMed/NCBI
29	Qiu K, Huang Z, Huang Z, He Z and You S: miR-22 regulates cell invasion, migration and proliferation in vitro through inhibiting CD147 expression in tongue squamous cell carcinoma. Arch Oral Biol. 66:92–97. 2016. View Article : Google Scholar : PubMed/NCBI
30	Chen JS, Li HS, Huang JQ, Dong SH, Huang ZJ, Yi W, Zhan GF, Feng JT, Sun JC and Huang XH: MicroRNA-379-5p inhibits tumor invasion and metastasis by targeting FAK/AKT signaling in hepatocellular carcinoma. Cancer Lett. 375:73–83. 2016. View Article : Google Scholar : PubMed/NCBI